Please assess the completion status of the following clinical trial:

Trial Title: Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~- AML with a poor prognosis defined according to the criteria below: LAM First line: Age \<60 years and unfavorable risk according to the 2017 ELN Age\> = 60 years old and intermediate or unfavorable risk according to the ELN 2017 LAM in Relapse: whatever the age~* ECOG \<= 2~* Patient eligible for intensive chemotherapy~* Informed consent~* Liver function tests: transaminases \<3x normal, bilirubin \<1.5X normal~* Creatinine clearance\> 60ml / min~* LVEF\> = 50%~Exclusion Criteria:~* Uncontrolled infection~* Hep B, C, HIV +~* History of diverticulosis / diverticulitis~* No social security or any other scheme~* Pregnant women or patient unable to take contraception(contraceptive pill, abstinence, IUD unauthorized) in case of fertility. A patient who cannot continue contraception for at least 3 months after the last injection of TOCILIZUMAB is not eligible.~* Lactating women~* Minors~* Adults under guardianship, curatorship or legal protection~* Hypersensitivity to one of the active substances or to one of the excipients~* Patients with tuberculosis~* Patients documented with active COVID

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).